New biologic GR1803 aims to tame lupus in early trial
NCT ID NCT07348055
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new biologic drug called GR1803 in 44 people with systemic lupus erythematosus, an autoimmune disease. The main goal is to check safety and see if the drug can control lupus activity. Participants must have moderate to severe lupus and have tried standard treatments. The trial is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GR1803 injection (a biologic drug)
- What this could lead to
- If successful, this could point toward a new treatment option for people with lupus, helping to control the disease and reduce symptoms.
- What could go wrong
- This is an early-phase trial with only 44 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTO IMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home workouts may rev up muscle energy in lupus patients
- Could weekly yoga ease fatigue and pain in autoimmune disease?
- Genetic clue may unlock why lupus hits some people harder
- New antibody therapy aims to tame lupus in early trial
- New injection aims to tame stubborn autoimmune diseases
- Scientists investigate why immunotherapy attacks the nervous system